meta|Evidence - COVID-19
click on circles to display study description...
baloxavir marboxil (n=10) vs. standard of care (n=10)
randomized controlled trial some concerns about risk of bias
Baloxavir marboxil
80 mg once a day orally on Day 1 and Day 4; for patients who are still positive in virological test, they can be given again on Day 7, no more than three additional doses.
Standard antiviral treatment
The existing antiviral treatment included lopinavir/ritonavir (400mg/100mg, bid, po.) or darunavir/cobicistat (800mg/150mg, qd, po.) and arbidol (200mg, tid, po.). All of them were used in combination with interferon-α inhalation (100,000 iu, tid or qid).
3 arms: favipiravir (n = 10), baloxavir marboxil (n=10), current antiviral treatment (n=10). Standard of care in both groups.
COVID 19 hospitalized
Adults 18-85 years of age, either man or woman, who have signed the informed consent voluntarily, with confirmed as COVID-19: positive results of throat swab or blood samples by real-time RT-PCR assay for 2019-nCoV; no difficulty in swallowing oral drugs; ability to follow the protocol according to the judgment of researchers. Subjects excluded if they had critical illness meeting one of the following conditions: respiratory failure and mechanical ventilation; shock; other organ failure requiring ICU monitoring and treatment;
Open-label
Single center, in The First Affiliated Hospital, Zhejiang University School of Medicine, China.
Time from randomization to clinical improvement, defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever came first.
No statistical plan available.
powered by vis.js Network